Switching to B/F/TAF from NNRTI-based regimens, particularly if RPV-based, showed high virological effectiveness and rare treatment discontinuations. No resistance mutations were detected at failure.
Effectiveness of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from Rilpivirine or Other Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in Virologically Suppressed People with HIV: A Retrospective Analysis (DRIVE-SWITCH Study)
R Gagliardini·A Antinori·Federica Forbici·Fabrizio Maggi·Lavinia Fabeni·Federico De Zottis·Alessandro Caioli·Gabriele Forcina·R Caldera·V Mazzotta·Rita Bellagamba·Sandrine Ottou·Ilaria Mastrorosa·Carmela Pinnetti·Elisabetta Grilli·Jessica Paulicelli·Marisa Fusto·Maria Maddalena Plazzi